

C4d in the portal stroma may be useful to determine the indication of postoperative plasma exchange and to assess the current and future protocols for ABO blood type-incompatible liver transplantation. Further studies are needed to clarify the significance of C4d and other markers of humoral immunity in ABO blood type-matched liver transplantation.

ACKNOWLEDGMENTS

We thank Dr. Daisuke Morioka (Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine) for his useful advice about the histology and treatment of the patients.

REFERENCES

1. Tanabe M, Shimazu M, Wakabayashi G, Hoshino K, Kawachi S, Kadomura T, et al. Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. *Transplantation* 2002;73:1959-1961.
2. Sekido H, Matsuo K, Takeda K, Morioka D, Kubota T, Tanaka K, et al. Successful adult ABO-incompatible liver transplantation: therapeutic strategy for thrombotic microangiopathy is the key to success. *Transplantation* 2003;75:1605-1607.
3. Usuda M, Fujimori K, Koyamada N, Fukumori T, Sekiguchi S, Kawagishi N, et al. Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation. *Transplantation* 2005;79:12-16.
4. Egawa H, Oike F, Buhler L, Shapiro AM, Minamiguchi S, Haga H, et al. Impact of recipient age on outcome of ABO-incompatible living-donor liver transplantation. *Transplantation* 2004;77:403-411.
5. Haga H, Egawa H, Shirase T, Miyagawa A, Sakurai T, Minamiguchi S, et al. Periportal edema and necrosis as diagnostic histological features of early humoral rejection in ABO-incompatible liver transplantation. *Liver Transpl* 2004;10:16-27.
6. Morioka D, Sekido H, Kubota K, Sugita M, Tanaka K, Togo S, et al. Antibody-mediated rejection after adult ABO-incompatible liver transplantation remedied by gammaglobulin bolus infusion combined with plasmapheresis. *Transplantation* 2004;78:1225-1228.
7. Collins AB, Schneeberger EE, Pascual MA, Saidman SL, Williams WW, Tolkoff-Rubin N, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. *J Am Soc Nephrol* 1999;10:2208-2214.
8. Behr TM, Feucht HE, Richter K, Reiter C, Spes CH, Pongratz D, et al. Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies. *J Heart Lung Transplant* 1999;18:904-912.
9. Magro CM, Pope Harman A, Klinger D, Orosz C, Adams P, Waldman J, et al. Use of C4d as a diagnostic adjunct in lung allograft biopsies. *Am J Transplant* 2003;3:1143-1154.
10. Ruiz P, Garcia M, Pappas P, Berney T, Esquenazi V, Kato T, et al. Mucosal vascular alterations in isolated small-bowel allografts: relationship to humoral sensitization. *Am J Transplant* 2003;3:43-49.
11. Yoshizawa A, Sakamoto S, Ogawa K, Kasahara M, Uryuhara K, Oike F, et al. New protocol of immunosuppression for liver transplantation across ABO barrier: the use of rituximab, hepatic arterial infusion, and preservation of spleen. *Transplant Proc* 2005;37:1718-1719.
12. Demetris AJ, Nakamura K, Yagihashi A, Iwaki Y, Takaya S, Hartman GG, et al. A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. *Hepatology* 1992;16:671-681.
13. International Panel. Banff schema for grading liver allograft rejection: an international consensus document. *Hepatology* 1997;25:658-663.
14. Zwirner J, Felber E, Schmidt P, Riethmuller G, Feucht HE. Complement activation in human lymphoid germinal centres. *Immunology* 1989;66:270-277.
15. Gugenheim J, Samuel D, Reynes M, Bismuth H. Liver transplantation across ABO blood group barriers. *Lancet* 1990;336:519-523.
16. Farges O, Kalil AN, Samuel D, Saliba F, Arulnaden JL, Debat P, et al. The use of ABO-incompatible grafts in liver transplantation: a life-saving procedure in highly selected patients. *Transplantation* 1995;59:1124-1133.
17. Straatsburg IH, Boermeester MA, Wolbink GJ, van Gulik TM, Gouma DJ, Frederiks WM, Hack CE. Complement activation induced by ischemia-reperfusion in humans: a study in patients undergoing partial hepatectomy. *J Hepatol* 2000;32:783-791.
18. Krukemeyer MG, Moeller J, Morawietz L, Rudolph B, Neumann U, Theruvath T, et al. Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection. *Transplantation* 2004;78:65-70.
19. Moeller J, Krukemeyer MG, Morawietz L, Schmeding M, Dankof A, Neumann U, et al. Molecular case report: IgVH analysis in acute humoral and cellular liver allograft rejection suggests a selected accumulation of effector B cells and plasma cells. *Virchows Arch* 2005;446:325-332.
20. Tanaka Y, Haga H, Egawa H, Okuno T, Miyagawa-Hayashino A, Tsuruyama T, et al. Intra-graft expression of recipient-type ABO blood group antigens: long-term follow-up and histological features after liver transplantation. *Liver Transpl* 2005;11:547-554.
21. Nakamura K, Murase N, Becich MJ, Furuya T, Todo S, Fung JJ, et al. Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model. *Am J Pathol* 1993;142:1383-1391.
22. Takaya S, Bronsther O, Iwaki Y, Nakamura K, Abu-Elmagd K, Yagihashi A, et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. *Transplantation* 1992;53:400-406.
23. Wu T, Abu-Elmagd K, Bond G, Demetris AJ. A clinicopathologic study of isolated intestinal allografts with preformed IgG lymphocytotoxic antibodies. *Hum Pathol* 2004;35:1332-1339.

Living Donor Liver Transplantation as a Second-Line Therapeutic Strategy for Patients With Hepatocellular Carcinoma

Yasutsugu Takada,¹ Mikiko Ueda,¹ Takashi Ito,¹ Seisuke Sakamoto,¹ Hironori Haga,² Yoji Maetani,³ Kohei Ogawa,¹ Mureo Kasahara,¹ Fumitaka Oike,¹ Hiroto Egawa,¹ and Koichi Tanaka¹

¹Department of Transplantation and Immunology, ²Department of Pathology, and ³Department of Radiology, Kyoto University, Kyoto, Japan

Living donor liver transplantation (LDLT) has evolved to represent an important surgical strategy for patients with hepatocellular carcinoma (HCC). However, due to disadvantages, including donor risks and higher rates of perioperative complications, LDLT has been considered as a second-line treatment in Japan. The present study retrospectively evaluated clinical outcomes for 93 patients with HCC who underwent LDLT at our institute, including 44 patients who exceeded Milan criteria (MC). A total of 73 patients (78%) displayed a history of previous treatment for HCC using various nontransplant methods. Median follow-up was 24 months (range, 1-76 months). At 4 years after LDLT, overall patient survival rate was 64%, with similar rates for within-MC and over-MC groups (68% vs. 59%, respectively; $P = 0.6548$). However, cumulative recurrence rate was significantly higher in the over-MC group than in the within-MC group (35% vs. 15%, $P = 0.0190$). Regarding history of conventional treatment for HCC before LDLT, patients who had received only 1-2 previous treatments showed significantly lower recurrence rates than patients with ≥ 3 treatments (9% vs. 37%, $P = 0.0411$). In conclusion, LDLT may constitute an optional treatment with a chance of cure for patients with otherwise uncontrolled disease. However, repeated nontransplant treatments for recurrent HCC prior to LDLT may increase the risk of recurrence and impair the survival advantages conferred by LDLT. *Liver Transpl* 12:912-919, 2006. © 2006 AASLD.

See Editorial on Page 896

The role of orthotopic liver transplantation in the management of hepatocellular carcinoma (HCC) has evolved significantly over the past decades. Initial experiences with orthotopic liver transplantation were limited to patients with extensive unresectable tumors, and were marked by uniformly dismal outcomes due to high rates of tumor recurrence.^{1,2} Those results evoked considerable interest in reexamining the staging guidelines to determine eligibility for orthotopic liver transplantation. This led to a study by Mazzaferro et al.³ who reported that 48 patients with a single tumor ≤ 5 cm in diameter or with ≤ 3 tumors all ≤ 3 cm in diameter, as identified by preoperative imaging, displayed survival

rates comparable to those of non-HCC liver transplant recipients. These Milan criteria (MC) are currently widely accepted as an effective method of selecting patients with early-stage HCC for curative orthotopic liver transplantation and have been incorporated into organ allocation systems.⁴

The prevalence of HCC is high in Japan, with around 30,000 deaths annually.⁵ While deceased donor liver transplantation has barely been available for patients with HCC, various treatment modalities, such as hepatic resection, percutaneous ethanol injection, radiofrequency ablation, and transarterial chemoembolization, have been developed, leading to improved outcomes.⁵⁻⁸ Against this background, living donor liver transplantation (LDLT) has recently emerged as a

Abbreviations: LDLT, living donor liver transplantation; HCC, hepatocellular carcinoma; MC, Milan criteria; MELD, model for end-stage liver disease; TNM, tumor, node, metastasis; JIS, Japan Integrated Staging.

Supported in part by grants from the Scientific Research Fund of the Ministry of Education and by Health and Labor Sciences Research Grants from the Ministry of Health, Labor and Welfare, Japan.

Address reprint requests to: Yasutsugu Takada, MD, Department of Transplantation and Immunology, Kyoto University, Kawara-cho 54, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. Telephone: 81-75-751-3660; FAX: 81-75-751-4877; E-mail: takaday@kuhp.kyoto-u.ac.jp

DOI 10.1002/lt.20642

Published online in Wiley InterScience (www.interscience.wiley.com).

new therapeutic option. Contrasting sharply with deceased donor liver transplantation, which utilizes a scarce public resource subject to an equitable allocation system, living donor liver grafts are dedicated to related recipients. LDLT thus allows the extension of selection criteria, since the acceptable recurrence rate is not absolute, but rather depends on donor organ availability.⁹ However, LDLT involves significant disadvantages, including risks to the live donor and higher perioperative morbidity and mortality compared with other treatment modalities. Given these risks, the argument has been made that early-stage HCC should initially be managed using resection or conventional methods if comparable overall survival is available, with LDLT held in reserve as a second-line option.^{10,11}

In February 1999, we started an LDLT program for patients with HCC using our own selection criteria that included tumors exceeding MC. We have previously reported initial results for 56 patients at a median follow-up of 11 months.¹² The present study reported extended results for 93 patients with HCC over a longer follow-up period. Risk factors for posttransplant mortality and recurrence were analyzed. The role of LDLT was investigated with regard to treatment strategies for cirrhotic patients with HCC.

PATIENTS AND METHODS

Patients

Patients with HCC met both of the following selection criteria for LDLT, approved by the ethics committee at Kyoto University: 1) HCC not suitable for resection or local ablation therapies due to advanced tumor spread, repeated uncontrolled recurrence or poor liver function reserve, and 2) exclusion of extrahepatic metastasis or macroscopic venous invasion on preoperative imaging. No restrictions were placed on the number or size of tumors. All patients were evaluated for the extent of tumor involvement using abdominal ultrasonography, contrast-enhanced computed tomography, brain and chest CT and bone scintigraphy.

Between February 1999 and September 2004, a total of 93 patients (64 men, 29 women) with HCC underwent LDLT at Kyoto University. During the same period, 51 patients were referred for but unable to undergo LDLT to our hospital. Reasons preventing LDLT included macroscopic vascular invasion ($n = 30$) or extrahepatic metastasis ($n = 15$) detected on imaging immediately before operation, no available donor ($n = 3$), and severely deteriorated patient condition ($n = 3$). Median age for the 93 patients who underwent LDLT was 54 years (range, 22-69 years). A total of 55 patients (59%) were hepatitis C virus antibody-positive, and 30 (32%) were hepatitis B surface antigen-positive, including 2 patients with coinfection. Child-Turcotte-Pugh classification was C for 44 patients (47%), B for 34 patients (37%), and A for 15 patients (16%). Median model for end-stage liver disease (MELD) score was 14 (range, 4-36). Of the 93 patients, 73 patients (78%) displayed a history of previous treatment for HCC using

various nontransplant methods including transarterial chemoembolization ($n = 63$), percutaneous ethanol injection or radiofrequency ablation ($n = 47$), or hepatic resection ($n = 11$). These treatments were performed in other hospitals not as a bridge to transplant, but with intent for curative ablation before referral to our institute. The remaining 20 patients (22%) had no history of HCC treatment before LDLT, in most cases due to advanced liver dysfunction.

All 93 patients were diagnosed with HCC immediately before LDLT. Tumor staging was determined by counting only viable and enhancing nodules on pretransplant CT. For patients who had undergone previous therapies, resected tumors or nodules that were judged as nonviable after percutaneous ethanol injection, radiofrequency ablation, or transarterial chemoembolization were not counted. According to the tumor, node, metastasis (TNM) staging criteria of the International Hepato-Pancreato-Biliary Association and the Liver Cancer Study Group of Japan,¹³ HCC was classified as stage I ($n = 14$), II ($n = 35$), III ($n = 42$) or IV-A ($n = 2$). A total of 49 patients (53%) met MC according to preoperative imaging, while 44 patients did not.

Of the 73 patients who had a history of previous nontransplant treatment, records of tumor stage at first diagnosis of HCC were available for 58 patients: stage I for 24 patients, stage II for 17 patients, stage III for 16 patients, and stage IV-A for 1 patient, according to TNM classification. While 42 patients met MC, 16 patients did not. Median period between first diagnosis of HCC and LDLT was 26 months (range, 2-168 months) in these 58 patients. At the time of LDLT, tumor stage was up-staged in 31 patients and 18 patients, down-staged in 5 and 6, and unchanged in 22 and 34, according to TNM classification and MC, respectively.

The Japan Integrated Staging (JIS) score combines the Child-Turcotte-Pugh classification and TNM staging by the Liver Cancer Study Group of Japan, and it has recently been proposed as a new prognostic staging system for patients with HCC.¹⁴ JIS score is obtained by adding tumor stage score (stage I, 0; stage II, 1; stage III, 2; stage IV, 3) and Child-Turcotte-Pugh score (Child-Turcotte-Pugh A, 0; B, 1; C, 2). JIS score in the 93 patients was 0 ($n = 2$), 1 ($n = 9$), 2 ($n = 26$), 3 ($n = 40$) or 4 ($n = 16$).

LDLT was performed using a right lobe graft for 92 patients and a left lobe graft for 1 patient. Operative procedures for donor and recipient surgery have been described elsewhere.^{15,16} Donors comprised 59 men and 44 women, with a median age of 41 years (range, 19-64 years). ABO blood-type matching was incompatible in 13 cases. Median graft-to-recipient body weight ratio was 1.03 (range, 0.73-1.69). As of the end of June 2005, median follow-up period was 24 months (range, 1-76 months).

Immunosuppression

The standard immunosuppression protocol comprised tacrolimus and low-dose steroid.¹⁷ However, 19 patients received steroid-free tacrolimus monotherapy as

TABLE 1. Preoperative Variables and Patient Survival (Univariate Analysis)

Variables	n	Number of Deaths*	4-Year Survival Rate	P	
Recipient age	≥60 years	23	1/3	80%	0.1501
	<60 years	70	9/16	59%	
Recipient gender	Male	64	7/12	65%	0.6229
	Female	29	3/7	60%	
Child-Turcotte-Pugh	A or B	49	7/9	61%	0.8806
	C	44	3/10	68%	
MELD	≥15	45	2/16	74%	0.1447
	≤14	48	8/3	53%	
Viral hepatitis	HBV	30	3/4	75%	0.4505
	HCV	55	5/12	62%	
Previous treatment	Positive	73	8/13	67%	0.2902
	Negative	20	2/6	52%	
Previous hepatectomy	Positive	11	1/2	68%	0.7421
	Negative	82	9/17	63%	
Donor age	≥50 years	32	7/4	56%	0.7590
	<50 years	61	3/15	68%	
ABO mismatch	Yes	13	2/4	23%	0.1305
	No	80	8/15	68%	
Graft-to-recipient body weight ratio.	≥1.0%	53	6/9	65%	0.6670
	<1.0%	40	4/10	62%	
Immunosuppression	With steroid	74	9/15	61%	0.5036
	Without steroid	19	1/4	72%	

*Number of dead patients: HCC-related death/HCC-nonrelated death.

an induction procedure in an attempt to reduce HCC recurrence. Patients who received ABO blood-type incompatible transplants were treated with preoperative plasma exchange or double filtration plasmapheresis to reduce anti-A or anti-B antibody titer. During the first 3 weeks postoperatively, prostaglandin E1 and additional steroids were administered via the portal vein or hepatic artery.¹⁸ Acute rejection episodes were documented based on liver histology and treated with steroid bolus if moderate or severe.

Statistical Analysis

Differences in qualitative variables were assessed using the Fisher exact or chi-square test, while differences in quantitative variables were analyzed using the Mann-Whitney test. Cumulative probability curves of survival or HCC recurrence were calculated using Kaplan-Meier methods, and differences between these curves were compared using the log-rank test. Any variable identified as significant ($P < 0.05$) in univariate analysis using the log-rank test was considered a candidate for multivariate analysis with Cox's proportional hazard regression model. Values of $P < 0.05$ were considered statistically significant. All statistical analyses were performed using the StatView 5 statistical software package (Abacus Concepts, Berkeley, CA).

RESULTS

Patient Survival

As of the end of June 2005, a total of 64 patients remained alive. Cause of death included recurrent HCC

($n = 10$), sepsis ($n = 7$), pneumonia ($n = 5$), peritonitis ($n = 4$), chronic rejection ($n = 1$), and other tumor-unrelated causes ($n = 2$). Overall patient survival rate at 4 years was 64%. Survival rate tended to be better for hepatitis B surface antigen-positive patients (75%) than for hepatitis C virus-positive patients (62%), although no significant difference was identified ($P = 0.4505$). None of the recipient and donor variables listed in Table 1, including MELD score, history of pretransplant treatment, or ABO blood-type compatibility, were significantly associated with long-term postoperative survival rate.

Analysis of preoperative tumor characteristics and patient 4-year survival (Table 2) revealed significantly lower survival rates in patients with tumors >5 cm in diameter than in patients with smaller tumors (20% vs. 69%, respectively; $P = 0.0259$). Unexpectedly, survival rates were similar for patients who met MC and those who did not (68% vs. 59% at 4 years, respectively; $P = 0.6548$) (Fig. 1). Patients with TNM stage III also tended to display poorer survival rates than patients with less advanced tumors, although no significant difference was identified (Table 2). With respect to JIS score, patients with a JIS score of 4 showed the lowest survival rate (58%), but no significant association was observed between JIS score and survival rate.

Recurrence of HCC

As of the time of writing, postoperative recurrence of HCC had occurred in 16 patients. First sites of recurrence comprised lung ($n = 5$), bone ($n = 3$), graft liver

TABLE 2. Univariate Analysis of Patient Survival and Recurrence Rate According to Preoperative Tumor Characteristics

Variables	n	4-Year Survival Rate	P	4-Year Recurrence Rate	P
Tumor size	>5 cm	12	20%	0.0259	67%
	≤5 cm	81	69%		
Tumor number	≤3	60	66%	0.7188	21%
	≥4	33	61%		
Milan criteria	Meet	49	68%	0.6548	15%
	Exceed	44	59%		
Distribution	Unilobar	44	64%	0.7064	25%
	Bilobar	49	64%		
TNM stage*	I	14	75%	0.1967	20%
	II	35	77%		
	III	42	49%		
	IVA	2	100%		
JIS score	0	2	50%	0.9513	NA
	1	9	78%		
	2	26	69%		
	3	40	62%		
	4	16	58%		
α-fetoprotein (ng/mL)	≥400	24	50%	0.2365	46%
	<400	69	69%		

Abbreviations: TNM, tumor, node, metastasis; NA, not applied.

*TNM stage: T factors are (1) single, (2) <2 cm, and (3) no vascular involvement. T1, fulfilling 3 factors; T2, fulfilling 2 factors; T3, fulfilling 1 factor; T4, fulfilling 0 factors. Stage I, T1N0M0; Stage II, T2N0M0; Stage III, T3N0M0; Stage IV-A, T4N0M0 or any T N1M0; Stage IV-B, any T N0-1M1.




Figure 1. Patient survival according to MC. Survival rates at 4 years after LDLT were similar for patients who met MC (n = 49, 68%) and for patients who exceeded MC (n = 44, 59%; P = 0.6548).

(n = 3), abdominal lymph nodes (n = 2), adrenal gland (n = 1), brain (n = 1), and right subphrenic space (n = 1). After excluding death without recurrence, overall cumulative recurrence rate was 25% at 4 years.

Univariate analysis of risk factors for recurrence showed that recurrence rates did not differ significantly between hepatitis B surface antigen- and hepatitis C virus-positive patients (32% vs. 19%, respectively; P = 0.3416) or patients with and without steroid-free induction therapy (6% vs. 31%, respec-

tively; P = 0.1076). Among preoperative tumor variables determined by imaging studies (Table 2), tumor diameter >5 cm, exceeding the MC and serum α-fetoprotein levels ≥400 ng/mL all represented significant predictors of higher recurrence rate. Recurrence rate was significantly higher in patients who exceeded MC than in patients who met these criteria (35% vs. 15%, respectively; P = 0.0190) (Fig. 2). However, multivariate analysis revealed that none of these variables represented significant independent risk factors (data not shown).

MC at First Diagnosis of HCC and Rates of Patient Survival and Recurrence after LDLT

For the 58 patients who had a history of previous nontransplant treatment for HCC and for whom records of tumor stage prior to any treatment were available, patient survival and HCC recurrence rates after LDLT were determined according to MC based on imaging at first diagnosis of HCC. Survival rates were similar for patients who had met MC (n = 42) and those who had not (n = 16) (71% vs. 69% at 4 years after LDLT, respectively; P = 0.8259) (Fig. 3A). Conversely, recurrence rate tended to be higher in patients who had exceeded MC than in patients who had met these criteria, although no significant difference was identified (37% vs. 13%, respectively; P = 0.0699) (Fig. 3B).





Figure 2. Cumulative recurrence rate according to MC. Cumulative HCC recurrence rate after LDLT was significantly higher for patients who exceeded MC (n = 44, 35%) than for patients who met MC (n = 49, 15%; P = 0.0190).

Pathological Findings and Recurrence


Correspondence of preoperative MC with the results of pathological analysis was evaluated in postoperative examinations of explanted livers. Completely ablated foci (100% necrosis) following pretransplant treatments were not counted as tumor. On pathological examination, 39 patients met so-called "pathological MC" and 54 did not. Accordingly, preoperative imaging underestimated the diagnosis in 13 patients (14%) and overestimated in 3 patients (3%). Of the 13 underestimated patients, HCC recurred in 4 patients. Univariate analysis of pathological findings (Table 3) revealed that tumor diameter >5 cm, tumor number ≥4, tumor grade indicating poor differentiation, and positive microvascular invasion were all significantly associated with postoperative recurrence. Using Cox's multivariate analysis (Table 4), pathological tumor number and poor differentiation were identified as independent risk factors for recurrence.

Effects of Previous Treatment Before LDLT

Patients were divided into 3 groups based on history of conventional treatment for HCC before LDLT: patients who primarily received LDLT without previous treatment (Group 1, n = 20); patients with 1-2 treatments (Group 2, n = 30); and patients with ≥3 treatments (Group 3, n = 43). Median period between first diagnosis of HCC and LDLT was 3 months in Group 1 (range, 1-15 months), 14 months in Group 2 (range, 2-70 months), and 36 months in Group 3 (range, 4-168 months). Preoperative liver function was most deteriorated in Group 1. Mean (± SD) preoperative MELD score was significantly higher in Group 1 (21 ± 8) than in Groups 2 (16 ± 7, P = 0.0414) or 3 (12 ± 6, P = 0.002). Conversely, the proportion of patients who exceeded MC before LDLT was significantly higher in Group 3 (63%) than in Groups 1 (35%) or 2 (33%, P = 0.020).



Patients at risk	0	10	20	30	40	50	60	70
Meet Milan	42	34	25	19	15	10	3	1
Exceed Milan	16	13	11	7	7	5	1	1



Patients at risk	0	10	20	30	40	50	60	70
Meet Milan	42	31	22	18	15	10	4	2
Exceed Milan	16	10	9	7	7	4	1	1

Figure 3. Survival and recurrence rates according to MC at first diagnosis of HCC. For the 58 patients who had a history of previous nontransplant treatment for HCC and for whom records of tumor stage prior to any treatment were available, patient survival and HCC recurrence rates after LDLT were determined according to MC based on imaging at first diagnosis of HCC. (A) Survival rates were similar for patients who had met MC (n = 42) and those who had not met MC (n = 16) (71% vs. 69% at 4 years after LDLT, respectively; P = 0.8259). (B) Recurrence rates tended to be higher in patients who had exceeded MC than in patients who had met these criteria, although differences were not significant (37% vs. 13%, respectively; P = 0.0699).

Based on postoperative examinations of explanted livers, microscopic venous invasion was significantly more frequent in Group 3 (51%) than in Groups 1 (21%) or 2 (33%, P = 0.0382). Postoperatively, HCC recurrence occurred in 3 patients in Group 1, 3 patients in Group 2, and 10 patients in Group 3. Survival rates at 4 years tended to be better for Group 2 (80%) than for Groups 1 (52%) and 3 (58%), although these differences were not significant (P = 0.0651 and P = 0.1042, respectively; Fig. 4A). Recurrence rates at 4 years were 23% for Group 1, 9% for Group 2, and 37% for Group 3. Rates were significantly lower for Group 2 than for Group 3 (P = 0.0411; Fig. 4B).

DISCUSSION

The present study showed that advanced stage of tumors in terms of tumor size, number, and α-fetoprotein

TABLE 3. Univariate Analysis of Pathological Tumor Characteristics and Recurrence Rate

Variables	n	4-Year Recurrence Rate	P
Tumor size	>5 cm	14	55%
	≤5 cm	79	19%
Tumor number	≤3	48	5%
	≥4	45	49%
Differentiation	Well	14	0%
	Moderate	59	23%
	Poor	20	60%
Microscopic venous invasion	Positive	37	42%
	Negative	56	14%

*Comparison between "Moderate" and "Poor."

TABLE 4. Multivariate Analysis of Pathological Tumor Factors and Recurrence

Variables	Risk Ratio	95% Confidence Interval	P
Tumor number	≤3	1	
	≥4	7.917	1.799-20.000
Differentiation	Well or Moderate	1	
	Poor	5.618	1.712-18.519

levels on preoperative evaluation is associated with increased postoperative recurrence. These results corroborate the findings of previous studies on deceased donor liver transplantation.¹⁹⁻²² In a study by Gondolesi et al.²³ of 36 patients with HCC treated using LDLT, tumor size >5 cm showed no significant effect on recurrence. Similarly, in our preliminary report on 56 patients,¹² recurrence rate did not differ between patients within and beyond MC. However, as patient numbers increased, the present study demonstrated that patients with tumors >5 cm in diameter experienced significantly higher rates of recurrence and mortality. In addition, patients who exceeded MC displayed significantly higher risk of recurrence.

Of note was the finding that patient survival rates were similar for patients who met MC and for patients who did not (Fig. 1). This discrepancy may be due to a short follow-up period, but it can also be explained by HCC-unrelated deaths due to postoperative complications occurring within a few months after LDLT. Infectious complications such as sepsis, pneumonia, and peritonitis were the most common causes of early mortality. As a rule, patients with early HCC were referred to our hospital for LDLT due to advanced liver cirrhosis. Mortality rates within 3 months were 18% for those within MC and 9% for those beyond MC, which may be associated with poorer preoperative condition for the former group as reflected by higher MELD score (18 ± 8 vs. 13 ± 6 , respectively; $P = 0.002$). Likewise, most patients who primarily received LDLT without previous treatment (Group 1, Fig. 4) were characterized by higher MELD scores and less advanced tumors. Survival rates for these patients were compromised by

HCC-unrelated death due to perioperative complications.

In the present study, 78 patients had received non-transplant treatments for HCC prior to LDLT. For these patients, tumor staging was determined by counting only viable and enhancing nodules on pretransplant computed tomography. Pretransplant tumor staging thus differed from that at first diagnosis of HCC. In the 58 patients for whom records of tumor stage prior to any treatment were available, 6 patients with tumors originally beyond MC had been down-staged with treatment and were assigned to the within-MC group before LDLT. Conversely, 18 patients were up-staged before LDLT. In an attempt to analyze outcomes according to primary tumor staging, survival and recurrence curves were determined for patients meeting and patients exceeding MC based on imaging at first diagnosis of HCC for the 58 patients (Fig 3). While patient survival rates did not differ significantly, recurrence rate tended to be higher in patients who had originally exceeded MC than in patients who had met MC. However, these differences were not significant, probably due to small number of patients involved.

Another controversy remains regarding indications for patients with early HCC. On the one hand, use of LDLT has been proposed for patients with early HCC accompanied by early-stage cirrhosis (Child-Turcotte-Pugh A), as a reasonable survival rate should be expected in weighing the risk of live donation.²⁴ Conversely, risking the life of a live donor for a patient who has alternative options of hepatic resection or other curative treatments with comparable long-term survival is unlikely to be ethically acceptable.²⁵ Patient




Figure 4. Survival and recurrence rates according to history of previous HCC treatment. According to history of conventional treatment for HCC before LDLT, patients were divided into 3 groups: Group 1, patients without previous treatment (n = 20); Group 2, patients with 1-2 treatments (n = 30); and Group 3, patients with ≥3 treatments (n = 43). (A) Survival rates at 4 years tended to be better for Group 2 (80%) than for Groups 1 (52%) and 3 (58%), although differences were not significant (P = 0.0651 and P = 0.1042, respectively). (B) Recurrence rate at 4 years was 23% for Group 1, 9% for Group 2, and 37% for Group 3. Recurrence rate was significantly lower for Group 2 than for Group 3 (P = 0.0411).

selection in our hospital is based on the latter policy: Patients with HCCs considered unsuitable for resection or local ablation therapies have been included in our program. In preoperative evaluations, a system for precise prognostic staging is essential for comparing outcomes between groups undertaking different therapeutic trials. Kudo et al.¹⁴ recently reported that JIS score offers a better system of prognostic staging for HCC than previous systems, in terms of both stratification ability and prognostic predictive power. In an analysis of 4,525 patients with HCC who received various conventional therapies, including hepatic resection, percu-

taneous ablation therapies and transarterial chemoembolization, patient survival was clearly stratified according to JIS score. The 5-year survival rates for patients were 73% for JIS 0 (n = 552), 52% for JIS 1 (n = 1,399), 33% for JIS 2 (n = 1,471), 13% for JIS 3 (n = 757) and 2% for JIS 4 (n = 244).¹⁴ This score system has not yet been validated outside Japan,²⁶ but it was applied to our series of LDLT recipients. As a result, both 4- and 5-year survival rates were 58%, even in JIS 4 patients. Although these figures should be carefully compared, LDLT may result in improved prognosis for patients with a JIS score ≥2.

Conversely, for patients with early HCC and preserved liver function (that is, JIS score of 0 or 1), hepatic resection or ablation therapies would represent the treatments of choice. However, high rates of recurrence occur even after curative treatment,²⁷ and the role of secondary or salvage transplantation has recently been discussed.^{24,25,28,29} Although prior hepatic resection may complicate the operative transplant procedure and increase the risk of postoperative complications,²⁴ postoperative survival in the 11 patients who received hepatic resection before LDLT was comparable to survival in the other 82 patients in this series (Table 1). On the other hand, transplantability at the time of recurrence is supposedly limited due to advanced tumor extension.²⁴ Even for patients who are considered eligible for salvage LDLT, the present study revealed significantly higher recurrence rates for patients with a history of ≥3 treatments for HCC before LDLT (Group 3) than for patients with only 1-2 treatments (Group 2, Fig. 4B). This result implies that repeated nontransplant treatments for recurrent HCC may increase the risk of microscopic vascular invasion and impair the survival advantages conferred by LDLT. For patients who develop HCC recurrence after conventional therapies, feasibility, optimal timing, and efficacy of LDLT as a second-line treatment should be determined in further studies.

In conclusion, although efforts to decrease early mortality due to surgical complications are essential to improve outcomes for LDLT, this technique may constitute an optional treatment with a chance of cure for patients displaying otherwise uncontrolled HCC. Patients who develop recurrent HCC should be referred for LDLT before repeated nontransplant therapies, if a living donor is available.

REFERENCES

1. Ringe B, Wittenkind C, Bechstein WO, Bunzendahl H, Pichlmayr R. The role of liver transplantation in hepatobiliary malignancy: A retrospective analysis of 95 patients with particular regard to tumor stage and recurrence. *Ann Surg* 1989;209:88-98.
2. Iwatsuki S, Gordon RD, Shaw BW, Starzl TE. Role of liver transplantation in cancer therapy. *Ann Surg* 1985;202:401-407.
3. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996;334:693-699.

4. United Network for Organ Sharing. Policy 3.6. Organ Distribution: Allocation of Livers. Available at: <http://www.unos.org>. Accessed June 24, 2005.
5. Omata M, Tateishi R, Yoshida H, Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation. *Gastroenterology* 2004;127(Suppl):S159-S166.
6. Esnaola NF, Mirza N, Lauwers GY, Ikai I, Regimbeau JM, Belghiti J, et al. Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan. *Ann Surg* 2003;238:711-719.
7. Itamoto T, Nakahara H, Tashiro H, Ohdan H, Hino H, Ochi M, et al. Indications of partial hepatectomy for transplantable hepatocellular carcinoma with compensated cirrhosis. *Am J Surg* 2005;189:167-172.
8. Ikeda M, Maeda S, Shibata J, Muta R, Ashihara H, Tanaka M, et al. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. *Oncology* 2004;66:24-31.
9. Schwartz M. Liver transplantation for hepatocellular carcinoma. *Gastroenterology* 2004;127(Suppl):S268-S276.
10. Todo S, Furukawa H, on behalf of the Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma. Experience in Japan. *Ann Surg* 2004;240:451-461.
11. Poon RT, Fan ST. Resection prior to liver transplantation for hepatocellular carcinoma: A strategy of optimizing the role of resection and transplantation in cirrhotic patients with preserved liver function. *Liver Transpl* 2004;10:813-815.
12. Kaihara S, Kiuchi T, Ueda M, Oike F, Fujimoto Y, Ogawa K, et al. Living-donor liver transplantation for hepatocellular carcinoma. *Transplantation* 2003;75(Suppl):S37-S40.
13. Makuuchi M, Belghiti J, Belli G, Fan ST, Lau JWY, Ringe B, et al. IHPBA concordant classification of primary liver cancer: Working group report. *J Hepatobiliary Pancreat Surg* 2003;10:26-30.
14. Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score. *Hepatology* 2004;40:1396-1405.
15. Inomata Y, Uemoto S, Asonuma K, Egawa H, Kiuchi T, Fujita S, et al. Right lobe graft in living donor liver transplantation. *Transplantation* 2000;69:258-264.
16. Kasahara M, Takada Y, Fujimoto Y, Ogura Y, Ogawa K, Uryuhara K, et al. Impact of with middle hepatic vein graft in right lobe living donor liver transplantation. *Am J Transplant* 2005;5:1339-1346.
17. Inomata Y, Tanaka K, Egawa H, Uemoto S, Ozaki N, Okajima H. The evolution of immunosuppression with FK506 in pediatric living related liver transplantation. *Transplantation* 1996;61:247-252.
18. Tanabe M, Shimazu M, Wakabayashi G, Hoshino K, Kawachi S, Kadomura T, et al. Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. *Transplantation* 2002;73:1959-1961.
19. Otto G, Heuschen U, Hofmann WJ, Krumm G, Herfarth C. Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma. A retrospective analysis. *Ann Surg* 1998;227:424-432.
20. Marsh JW, Dvorchik I, Subotin M, Balan V, Rakela J, Popechitelev EP, et al. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: A pilot study. *Hepatology* 1997;26:444-450.
21. Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. *Hepatology* 2001;33:1080-1086.
22. Hemming AW, Cattral MS, Reed AI, Van der Wert WJ, Greig PD, Howard RJ. Liver transplantation for hepatocellular carcinoma. *Ann Surg* 2001;233:652-659.
23. Gondolesi GE, Roayaie S, Munoz L, Kim-Schluger L, Schiano T, Fishbein TM, et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma. Extending UNOS priority criteria. *Ann Surg* 2004;239:142-149.
24. Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma in cirrhosis. A reasonable strategy? *Ann Surg* 2003;38:508-519.
25. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function. Implications for a strategy of salvage transplantation. *Ann Surg* 2002;235:373-382.
26. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, et al. Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort. *Hepatology* 2005;41:707-716.
27. Carr BI. Hepatocellular carcinoma: Current management and future trends. *Gastroenterology* 2004;127(Suppl):S218-S224.
28. Belghiti J, Cortes A, Abdalla EK, Regimbeau JM, Prakash K, Durand F, et al. Resection prior to liver transplantation for hepatocellular carcinoma. *Ann Surg* 2003;238:885-893.
29. Sala M, Fuster J, Llovet JM, Navasa M, Sole M, Varela M, et al. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: An indication for salvage liver transplantation. *Liver Transplantation* 2004;10:1294-1300.

Identification of novel defective HCV clones in liver transplant recipients with recurrent HCV infection

A. Iwai,¹ H. Marusawa,¹ Y. Takada,² H. Egawa,² K. Ikeda,¹ M. Nabeshima,¹ S. Uemoto² and T. Chiba¹ ¹Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; and ²Department of Transplantation Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Received October 2005; accepted for publication January 2006

SUMMARY. Patients with recurrent hepatitis C after liver transplantation usually have a high viral load and are generally resistant to interferon (IFN)- α 2b plus ribavirin (RBV) therapy. However, it remains unclear whether pretreatment viral titre determines the effectiveness of combination therapy, especially in patients with a high viral load. The aim of this study was to identify the viral factors associated with a sustained virological response (SVR) to antiviral therapy in patients with recurrent hepatitis C after living-donor liver transplantation. Twenty-three patients with recurrent hepatitis C received combination therapy of IFN- α 2b plus RBV. SVR was achieved in 7 of the 23 patients (30.4%). Predictive factors for SVR included a 2 log₁₀ decline in Hepatitis C virus (HCV) RNA at 2 weeks after the start of therapy and disappearance of HCV RNA at 4 or 24 weeks after the start of therapy. As the pretreatment high

viral load showed no association with SVR, we asked whether other viral factor was associated with the response to the combination therapy in transplant recipients. We found the several novel defective HCV clones in 4 of 12 recipients' sera. All defective HCV clones had deletions in the envelope region. Interestingly, no patients with defective clones showed a prompt decrease in HCV RNA after the start of IFN- α 2b plus RBV therapy. Thus, early decline in serum HCV RNA after treatment was closely associated with SVR. The circulating defective HCV clones are present and might be associated with the response to the combination therapy in patients with recurrent hepatitis after liver transplantation.

Keywords: hepatitis C virus genome, interferon, liver transplantation, ribavirin, sustained virological response.

INTRODUCTION

Hepatitis C virus (HCV) infection is one of the leading causes of end-stage liver disease; thus, HCV-related chronic liver disease is a common indicator for liver transplantation. However, recurrent hepatitis in the liver allograft develops in most recipients [1]. Unlike immunocompetent individuals, HCV recurrence in patients who receive a liver

transplant results in severe liver damage at an accelerated rate, leading to recurrent cirrhosis within 5 years [2,3]. Moreover, several investigators have shown that HCV recurrence is more severe in living-donor liver transplantation (LDLT) than in orthotopic liver transplantation (ORLT) [4,5]. LDLT provides the only access to donor organs in countries like Japan, where cadaveric donors are not available. Therefore, establishment of highly effective treatment strategies for recurrent hepatitis C after liver transplantation is strongly required.

Hepatitis C in transplant recipients differs from that in immunocompetent individuals in several aspects [6]. Most recipients have extremely high viral loads as a result of their immunosuppressive conditions [6]. HCV baseline viral load is an independent factor associated with poor response to interferon (IFN)- α 2b plus ribavirin (RBV) combination therapy [7,8]. Thus, liver transplant patients with recurrent hepatitis C are generally resistant to antiviral treatment. In fact, sustained virological response (SVR) in ORLT recipients by IFN- α 2b plus RBV combination therapy has only been observed in up to 30% of patients [9,10]. Thus, resistance to

Abbreviations: IFN, interferon; RBV, ribavirin; SVR, sustained virological response; LDLT, living-donor liver transplantation; HCV, hepatitis C virus; ORLT, orthotopic liver transplantation; PMN, polymorphonuclear; HCC, hepatocellular carcinoma; HLA, human leukocyte antigen; MU, million units; RT-PCR, reverse transcriptase-polymerase chain reaction; HBV, hepatitis B virus; 5'-UTR, 5'-untranslated region; NS, nonstructural protein; E1, envelope glycoprotein-1; E2, envelope glycoprotein-2.

Correspondence: Dr Tsutomu Chiba, Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, 54 Kawara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
E-mail: chiba@kuhp.kyoto-u.ac.jp

IFN- α 2b plus RBV combination therapy in recipients with HCV recurrence is a challenging obstacle at present. Therefore, the aim of this study was to determine viral factors other than genotype 1b and high viral load that influence responsiveness to IFN- α 2b plus RBV combination therapy in patients with recurrent hepatitis C after LDLT.

MATERIALS AND METHODS

Patients

Between March 1999 and December 2004, 100 patients underwent LDLT at Kyoto University Hospital as a result of end-stage liver disease caused by HCV infection. Recurrence of chronic active hepatitis C was histologically confirmed on a biopsy sample in 49 patients. Indicators for IFN- α 2b plus RBV combination therapy in these patients included high serum values of alanine aminotransferase (above upper limits of normal >27 IU/L), with haemoglobin levels >8 g/dL, total polymorphonuclear (PMN) counts $>1500/\text{mm}^3$, platelet counts $>50\ 000/\text{mm}^3$, normal renal function (serum creatinine <1.5 mg/dL and/or creatinine clearance >50 mg/mL) and no hepatocellular carcinoma (HCC) recurrence. Of 49 patients, 30 received treatment with IFN- α 2b plus RBV combination therapy (Schering-Plough, Kenilworth, NJ, USA). Among them, 23 patients, who were sequentially monitored at the same hospital throughout the treatment period and 24 weeks after cessation of treatment, were enrolled for further analyses. At the time of entry, liver biopsy specimens were assessed by an experienced hepatopathologist using the METAVIR score; the fibrosis stage was defined as F0 (no fibrosis), F1 (mild fibrosis), F2 (moderate fibrosis), F3 (severe fibrosis) and F4 (cirrhosis) [11]. The HCV genotype was determined using a commercially available reverse transcriptase-polymerase chain reaction (RT-PCR) assay that can distinguish genotypes 1a, 1b, 2a, 2b, 3a and 3b of HCV (Monitor HCV Coregenotyping; SRL, Tokyo, Japan). Serum HCV RNA was measured before, at 2, 4, 12, 24 and 48 weeks during therapy and every 4 weeks after the end of therapy, using the Roche Amplicor HCV 2.0 assay (Roche Diagnostics, Branchburg, NJ, USA). Serum samples were diluted and retested by the same assay, when serum HCV RNA load was over 850 kIU/mL. All patients received tacrolimus-based immunosuppression [12]. The ethics committee of Kyoto University approved the studies, and informed consent for participation in the study was obtained from all patients.

Typing of human leukocyte antigen class

We performed human leukocyte antigen (HLA) typing by PCR amplification with MicroSSP HLA DNA typing trays (One Lambda, Canoga Park, CA, USA) according to the manufacturer's instructions in patients. The amplified DNA was electrophoresed and visualized on ethidium-bromide-

stained 2% agarose gels. HLA analysis included 17 HLA-A, 19 HLA-B and 16 HLA-DR alleles.

Study design

Patients were treated with 6 million units (MU) or 3 MU of recombinant IFN- α 2b three times a week for 48 weeks (3 MU IFN- α 2b was used when platelet counts were $<100\ 000/\text{mm}^3$ or PMN counts were $<2000/\text{mm}^3$ before therapy) plus oral RBV for the first 24 weeks. RBV dosage was based on the weight of each patient: patients less than 60 kg were administered 600 mg, and patients greater than 60 kg received 800 mg. IFN dosage was reduced to 3 MU if platelet counts dropped to $<100\ 000/\text{mm}^3$ or if PMN counts dropped to $<2000/\text{mm}^3$ during therapy. When haemoglobin levels before treatment were less than 10 g/dL, RBV dosage was reduced to 400 mg in patients weighing less than 60 kg and to 600 mg in patients weighing more than 60 kg. The combination therapy was discontinued when haemoglobin levels, total PMN counts or platelet counts were observed to be less than the eligible levels mentioned above during therapy. SVR was defined as no detectable HCV RNA by qualitative assay at least 24 weeks after cessation of therapy.

Detection of defective HCV RNA

Serum samples for the detection of defective HCV RNA were taken before the start of IFN- α 2b and RBV administration. Total RNA was extracted from 250 μL of serum using Sepasol® RNA II super (Nacalai Tesque, Kyoto, Japan), according to the manufacturer's protocol. The extracted RNA was resuspended in 10 μL of RNase-free water and 5 μL of each RNA sample was used in each reaction. RT-PCR was performed using the One Step RNA PCR Kit (Takara, Tokyo, Japan), as described earlier [13]. The RT-PCR primers, which were designed from the reference sequence of HCV genotype 1b (GenBank Accession No. #D90208), were shown in Table 1. All PCR products were analysed by electrophoresis in 1.2% agarose gels stained with ethidium bromide. Subcloning of purified DNA was performed using the pGEM-T easy vector (Promega, Madison, WI, USA) [14]. At least 30 colonies on each plate were picked using white/blue colony selection, and plasmid DNA was extracted and then purified by ethanol precipitation. Each purified DNA sample was sequenced at least three times using an ABI Prism Big Dye Terminator Ready Reaction Kit (Applied Biosystems, Foster City, CA, USA) [14]. To determine the defects in the HCV genome, the sequence of each sample was compared with the registered HCV genome sequence, as described above. The serum of a healthy HCV-RNA-negative volunteer was used as a negative control. The full RNA genome of HCV was synthesized *in vitro* from the pM1E plasmid (inserted genotype 1b sequence of HCV full genome) using a MEGAscript T7 Kit (Ambion, Austin, TX, USA) and used as a positive control [15].

Table 1 Data of the using primer sets

Primer name	Sequence	Expected size of amplification
HCV-P1	Sense: 5'-CGCCGACCTCATGGGGTACA-3' Antisense: 5'-TGGTGTACATTTGGGTGATT-3'	2919 bp
HCV-P2	Sense: 5'-TGCTCTTTCTCTATCTTCCT-3' Antisense: 5'-GTGATGATGCAACCAAGTAG-3'	2618 bp
HCV-P3	Sense: 5'-TCTTTGCCGGCGTTGACGGG-3' Antisense: 5'-TAGGGTGGTGAAGGAACAGG-3'	957 bp

Table 2 Baseline characteristics of patients ($n = 23$)

Age (years)*	54.5 (39–68)
Gender (male/female)	12/11
Disease for LDLT (LC/LC + HCC)	12/11
Fibrosis grade before therapy (FO/F1/F2/F3)	7/10/5/1
Alanine aminotransferase (IU/L)*	191.9 (53–845)
White blood cell counts (per mm ³)*	4500 (1300–9600)
Haemoglobin (g/dL)*	12.2 (9.80–14.7)
Platelet counts ($\times 10^4$ /mm ³)*	17.1 (5.10–47.7)
Prothrombin time (INR)*	1.20 (0.87–3.09)
Total bilirubin (mg/dL)*	2.43 (0.50–13.4)
Creatinine (mg/dL)*	0.77 (0.50–1.60)
Virus genotype (1b/2a/2b/others)	20/1/1/1
Pretreatment viral loads (kIU/mL)	
<100	0
100–850	6 (120, 347, 357, 630, 800, 830)†
>850	17 (860, 880, 920, 950, 1020, 1060, 1420, 1470, 1790, 1920, 1940, 1960, 2320, 2940, 3210, 4730, 21200)†
IFN dosage (300 MU/600 MU)	9/14

LDLT, living-donor liver transplantation; LC, liver cirrhosis; HCC, hepatocellular carcinoma; IFN, interferon; MU, million units.

*Values are median (range).

†Actual viral load of each patient.

Statistical analysis

Results are expressed as mean or median and range (minimum and maximum). Pretreatment values were compared using the Mann–Whitney *U*-test. Categorical variables were analysed by Fisher's exact test. $P < 0.05$ was considered statistically significant. *P* values of HLA data were corrected by multiplying the number of alleles tested in each locus: A ($n = 9$), B ($n = 22$) and DR ($n = 11$) using Bonferroni correction test.

RESULTS

Baseline characteristics of patients

The baseline clinical and virological characteristics of 23 patients who received IFN- α 2b plus RBV combination ther-

apy after LDLT are summarized in Table 2. All patients lacked evidence of coinfection with hepatitis B virus (HBV) or human immunodeficiency virus before LDLT. Of 23 patients, 20 (87.0%) were infected with HCV genotype 1b. Before treatment, all patients had serum HCV RNA levels over 100 kIU/mL by the Amplicor HCV 2.0 assay. Moreover, HCV RNA levels were greater than 850 kIU/mL (ranging from 850 to 21 200 kIU/mL) in 17 cases (73.9%), which is equivalent to 8.5×10^5 – 2.12×10^7 copies/mL HCV RNA by RT-PCR (Roche) [16], indicating that a majority of the patients in this study had high baseline viral loads before treatment.

Of the 23 patients allocated to a 48-week schedule, 15 (65.2%) completed treatment and 8 (34.8%) withdrew from the treatment protocol because of adverse events, such as thrombocytopenia. Of these eight patients, the median duration of IFN treatment, from initiation to withdrawal of

	SVR (n = 7)	Non-SVR (n = 8)	P value
Age (years)*	54.9 ± 6.15	52.4 ± 8.80	0.685
Gender (male)	4 (57.1%)	4 (50.0%)	0.595
No fibrosis before treatment	1 (14.3%)	2 (25.0%)	0.554
ALT (IU/L)*	152.4 ± 119.2	178.6 ± 100.8	0.643
Prothrombin time (INR)*	1.07 ± 0.17	1.10 ± 0.16	0.563
Total bilirubin (mg/dL)*	0.84 ± 0.31	2.10 ± 3.39	0.685
Creatinine (mg/dL)*	0.76 ± 0.24	0.73 ± 0.17	0.862
Virus genotype non-1b	2 (28.6%)	1 (12.5%)	0.446
Actual virus loads†	953 (120–1960)	1040 (347–21200)	0.177
Virus loads (>850 kIU/mL)	5 (71.4%)	6 (75.0%)	0.662
Reduction of IFN dose	1 (14.3%)	1 (12.5%)	0.733
Reduction of RBV dose	3 (42.9%)	4 (50.0%)	0.595
IFN dosage (300 MU)	3 (42.9%)	3 (37.5%)	0.622
Disappearance of HCV RNA			
4 weeks	5 (71.4%)	0 (0%)	0.007‡
12 weeks	6 (85.7%)	3 (37.5%)	0.084
24 weeks	7 (100%)	3 (37.5%)	0.019‡
Decline of HCV RNA by 2 log ₁₀ in 2 weeks	6 (85.7%)	2 (25.0%)	0.032‡

Table 3 Predictive factors for SVR

Statistics are calculated using either Mann–Whitney *U*-test or Fisher exact test; SVR, sustained virological response; ALT, alanine aminotransferase; IFN, interferon; RBV, ribavirin; MU, million units.

*Values are mean ± SD or median (range).

†Values are median (range).

‡Statistically significant difference ($P < 0.05$).

the combination therapy, was 4 weeks (ranging from 1 to 15 weeks). Of the 15 patients who completed the treatment protocol, dose modification of either IFN- α 2b or RBV was required in seven patients (46.7%). Among them, two patients had a redactor of IFN- α 2b dose from 6 to 3 MU because of neutropenia and thrombocytopenia. Nine patients had a decreased dose of RBV during the therapy for the progressive anaemia. After treatment was completed, median blood levels returned to normal within 8 weeks in all patients. No patients died during the study period.

Factors associated with a sustained virological response

Sustained virological response was achieved in 7 of the 23 patients (30.4%). As none of the eight patients who withdrew from the study achieved SVR, completion of the combination therapy was a predictive factor of SVR ($P = 0.026$ and <0.05). Next, to determine predictive factors for the efficiency of the combination treatment in the 15 patients who completed the combination therapy, we examined the correlation between response to antiviral therapy and various baseline factors (Table 3). Two of three patients (66.7%) with the HCV genotype non-1b achieved SVR, whereas 5 of the 20 patients (25.0%) with the HCV genotype 1b achieved SVR. Among the 15

patients who had a pretreatment viral titre over 850 kIU/mL and infected with genotype 1b, four (26.7%) achieved SVR, whereas one (20.0%) of the five patients with a viral titre below 850 kIU/mL and genotype 1b achieved SVR. In addition, there was no relationship between SVR and actual viral load in each case ($P = 0.177$). These results showed that SVR was not significantly related to the baseline viral load before treatment in these transplant recipients with genotype 1b.

We then analysed the time course of viral load during IFN- α 2b plus RBV combination therapy after LDLT. All seven cases with SVR cleared serum HCV RNA at 24 weeks after combination therapy, whereas HCV RNA was undetectable in three of the eight nonresponsive (non-SVR) patients (37.5%) who completed the treatment. Moreover, HCV RNA was undetectable in five of the seven SVR patients (71.4%) at 4 weeks after the start of treatment, whereas all eight non-SVR patients were HCV-RNA-positive at the same period ($P < 0.05$). Consistent with the rate of HCV disappearance in sera, a 2 log₁₀ decrease in HCV RNA was observed 2 weeks after combination therapy in six of the seven SVR patients, a significantly greater decline compared with that observed in non-SVR patients (two of the eight patients) ($P < 0.05$). There was no relationship between SVR and other baseline factors.

Detection of defective HCV RNA in sera of post-LDLT patients with HCV recurrence

Hepatitis C virus genotype 1b and baseline high viral concentrations are independent factors associated with poor response to IFN- α 2b plus RBV combination therapy [7,8]. In this study, a substantial number of patients with extremely high viral load (above 850 kIU/mL) obtained SVR with the combination treatment. We therefore assessed whether serum HCV RNA titre, as determined by the widely used quantitative RT-PCR assay using the primer set specific for the 5'-untranslated region (5'-UTR) of HCV RNA [17-19], reflected the actual viral activity in patients with extremely high viral titre (above 850 kIU/mL) and genotype 1b under immunosuppressive conditions after LDLT. To determine the viral population circulating in the sera of these patients, we investigated HCV clones in 15 patients with genotype 1b and a pretreatment viral load above 850 kIU/mL. To amplify the HCV genome, we designed various primer sets spanning the 5'-UTR and the nonstructural protein (NS) 3 regions (Fig. 1a). Using conventional 5'-UTR primers, we confirmed that the amplified signal derived from HCV RNA corresponded to the expected size in all the 15 patients (data not shown). In contrast, using the primer sets spanning from the core to the NS3 region (HCV-P1 and HCV-P2), HCV sequences were not amplified in three patients, suggesting

the presence of nucleotide alterations in the region of the HCV genome corresponding to these primer sequences. We confirmed that the signal amplified by the HCV-P1 primer set corresponded to the expected size in the 12 patients, from whom HCV sequences were amplified. Notably, we also revealed sequences that were smaller than expected in the sera of four patients (patients 1, 2, 3 and 6), suggesting there was a deletion in the HCV genome. As shown in Fig. 1a, the expected size of HCV RNA amplified by the HCV-P1 primer set was 2919 bp. In addition to this fragment, however, other signals with a smaller sequence size were detected in patients 1, 2, 3 and 6 (Fig. 1b; data for patients 2 and 3 are shown).

Slippage can occur during the target amplification process of *Taq* DNA polymerase [20]. Therefore, it is possible the HCV





Fig. 1 Defective HCV clones detectable in the sera of highly viraemic patients with recurrent hepatitis C after LDLT. (a) Schematic presentation of the HCV genome and the primer sets used in this study. The sense and antisense primers specific for that part of the HCV sequence spanning 5'-UTR and NS3 are shown as arrows. The primer set specific for the 5'-UTR is generally used for the quantitative RT-PCR-based assay. Both HCV-P1 and HCV-P2 primer sets amplified the regions spanning from the core to the NS3 region and produced fragments of 2919 and 2618 bp in size, respectively. Amplification using the HCV-P3 primer set resulted in 957 bp fragments. 5'-UTR, 5'-untranslated region; E1, envelope glycoprotein-1; E2, envelope glycoprotein-2; NS, nonstructural protein. (b) Total RNA was extracted from the pretreatment sera of three patients (patients 2, 3 and 5). HCV RNA was determined by RT-PCR using the HCV-P1 primer sets. Black arrowheads indicate the fragment size of 2919 bp, corresponding to HCV RNA sequences of the expected size. Shorter fragments derived from HCV RNA amplification are indicated with white arrowheads. Lane M = λ DNA (Toyobo, Tokyo, Japan), digested with *Eco*RI and *Hind*III restriction enzymes, as a molecular weight marker. (c) The full-length HCV RNA genome was synthesized *in vitro* and used as a template in the RT-PCR assay as a positive control (left panel). Total RNA was prepared from the sera of patient 3 (middle panel) and a healthy individual without HCV infection (right panel). HCV RNA was amplified by RT-PCR using the primers HCV-P1, HCV-P2 and HCV-P3 and each RNA specimen as a template. Black arrowheads indicate expected sizes of fragments corresponding to the wild-type HCV generated by HCV-P1 (2919 bp, lane P1), HCV-P2 (2618 bp, lane P2) and HCV-P3 (957 bp, lane P3). Shorter fragments of 1374 bp (lane P1) and 947 bp (lane P2) are shown as white arrowheads (middle panel). Note that the HCV-P3 primer set only amplified the fragment corresponding to the wild-type clone with the expected size (957 bp) in patient 3. Lane M = λ DNA, digested with *Eco*RI and *Hind*III restriction enzymes, as a molecular weight marker.

RNA deletion was due to an artefact during PCR amplification. To exclude this possibility, we amplified HCV sequences using several primer sets that spanned various regions spread over the HCV RNA genome in these patients (Fig. 1a). First, using *in vitro* synthesized full-length HCV RNA as a template, we confirmed that HCV fragments of the expected size (2919, 2618 and 957 bp) were amplified by the three different primer sets (HCV-P1, HCV-P2 and HCV-P3), respectively (Fig. 1c, left panel). Notably, we detected shorter HCV RNA fragments in the sera of transplant recipients with high viral loads. For example, using primer sets HCV-P1 and HCV-P2, short fragments of 1374 and 963 bp, respectively, as well as HCV RNA fragments of the expected sizes, were detected in the sera of patient 3 (Fig. 1c, middle panel). In contrast, the signals derived from the amplification using the primer set spanning the envelope region (HCV-P3) mainly included a fragment corresponding to wild-type HCV accompanied by a faint short signal. Taken together, these findings suggest that the shorter HCV RNA fragments were not an artefact of the PCR and might be derived from the sequences around the region between envelope glycoprotein 1 (E1) and NS2 in defective HCV clones.

To determine the internal structure of these deletions, all amplified fragments from four patients were subcloned for further sequence analyses. Schematic representations of defective HCV RNA detected in the sera of these patients are shown in Fig. 2. All defective clones identified had complete deletion of the E1 and envelope glycoprotein 2 (E2) regions of HCV RNA; that is, the shorter HCV clones detected in patients 1 and 6 contained the 3'-terminal part of the core, and the clones detected in patients 2 and 3 were also defective in the C-terminal of the core sequences. Nucleotide deletions in three (patients 1, 2 and 3) of four cases did not lead to a change in the reading frame, whereas the deletion in the coding sequence in patient 6 resulted in a change in the reading frame and thus a new stop codon was generated at the 886th amino acid. Although fragments of other sizes detected in these sera were also amplified by RT-PCR, sequence analyses revealed that these fragments were not identical to HCV RNA, suggesting that they were nonspecific PCR artefacts. To carry out quantitative analyses on the defective HCV clones, we performed northern blotting for HCV RNA using the extracted total RNA from sera as templates. However, signals derived from full and defective genomes were too weak to detect (data not shown).

Clinical significance of the defective HCV clones

Because a substantial number of post-LDLT patients with high viral loads had circulating defective HCV, we investigated the relationship between the presence of the defective HCV in sera and the various clinical factors in the 12 patients whose HCV RNA could be amplified by the HCV-P1 primer set (Table 4). Interestingly, none of the four patients



Patient no.	HCV-RNA (KIU/L)	HCV clone Genbank ID	Deleted region
1	850	AF165047	E1, E2, p7, NS2
2	1060	AF165058	Core, E1, E2, p7, NS2
3	2960	AF165058	Core, E1, E2
6	4020	AF207753	E1, E2, p7, NS2

Fig. 2 Schematic presentation of defective HCV clones in the sera of LDLT recipients with recurrent hepatitis C. The values in the schema indicate the nucleotide numbers from the first ATG of the core region in HCV RNA. Nucleotide and amino acid sequences immediately before and after the deleted region of the HCV genome are shown. The frame shift of the open reading frame occurred in the deleted HCV genome in patient 6; the changed amino acid sequence is shown under the codon, and the asterisk indicates a novel stop codon. E1, envelope glycoprotein-1; E2, envelope glycoprotein-2; NS, nonstructural protein.

with defective HCV RNA showed a 2 log₁₀ decrease in HCV RNA within 2 weeks of the administration of combination therapy. In contrast, six of the eight patients (75.0%) whose sera contained only the wild-type HCV showed a prompt 2 log₁₀ decrease in HCV RNA within 2 weeks of the administration of combination therapy ($P < 0.05$). Multivariate analysis, to assess whether the presence of defective clones significantly correlated with SVR, was difficult to carry out because of the limited number of patients. The patients without defective clones comprised three SVRs, two non-SVRs and three who withdrew from the study.

Table 4 The association between the presence of HCV defective clones and the clinical factors

	Defective clones		P value
	Presence (n = 4)	Absence (n = 8)	
Age (years)*	56.3 ± 3.59	52.5 ± 7.21	0.396
Gender (male)	3 (75.0%)	4 (50.0%)	0.424
No fibrosis before treatment	0 (0%)	4 (50.0%)	0.141
ALT (IU/L)*	152.5 ± 128.3	271.0 ± 241.5	0.308
Prothrombin time (INR)*	1.05 ± 0.04	1.34 ± 0.72	0.497
Total bilirubin (mg/dL)*	0.85 ± 0.33	3.52 ± 5.00	0.552
Creatinine (mg/dL)*	0.80 ± 0.18	0.74 ± 0.20	0.497
IFN dosage (300 MU)	3 (75.0%)	5 (62.5%)	0.594
Decline of HCV RNA by 2 log ₁₀ in 2 weeks	0 (0%)	6 (75.0%)	0.030†
SVR of therapy	1 (25.0%)	3 (37.5%)	0.594

Statistics are calculated using either Mann-Whitney *U*-test or Fisher exact test. The data on 12 patients whose HCV RNA in the sera could be amplified by the primer sets spanning from the core to the non-structural protein 3 region are shown. ALT, alanine aminotransferase; IFN, interferon; MU, million units; SVR, sustained virological response.

*Values are mean ± SD.

†Statistically significant difference ($P < 0.05$).

Although two patients lacking defective clones were defined as non-SVR, they also showed the 2 log₁₀ decline in HCV RNA within 2 weeks of the administration of combination therapy and the disappearance of HCV RNA during the IFN- α 2b plus RBV therapy. The patients with defective clones comprised one SVR, two non-SVRs and one who withdrew from the study. The SVR patient, in whom the defective HCV was detected before treatment, had a slow decline in viral titre, and disappearance of HCV RNA was achieved at 24 weeks of therapy.

DISCUSSION

To date, IFN- α 2b plus RBV combination therapy has become one of the gold standards for the treatment of recurrent hepatitis C following liver transplantation [6,21,22]. However, little is known about factors that predict the efficacy of the combination therapy in posttransplant patients with extremely high viral load under immunosuppressive conditions. In this study, we have demonstrated that combination treatment with IFN- α 2b plus RBV induced SVR in 30.4% of patients with recurrent hepatitis C after LDLT. This SVR rate was similar to the data from previous studies of ORLT patients [9,10]. We also revealed that a 2 log₁₀ decline in HCV RNA levels within 2 weeks after starting the treatment and the clearance of HCV RNA at 4 or 24 weeks after the start of treatment was predictive for SVR in these patients. Our findings are in agreement with previous studies showing that the early decline of HCV RNA following the start of combination therapy is a predictive factor for SVR in patients

with HCV-induced chronic liver disease without transplantation [23,24].

Hepatitis C virus reinfection in posttransplant patients differs from HCV infection in immunocompetent nontransplant patients in several aspects. One of the most striking features of transplant recipients with recurrent hepatitis C is their extremely high viral load as a result of immunosuppressive conditions [6]. In fact, most patients examined in this study had pretreatment viral titres over 850 kIU/mL; this extremely high viral load is rarely observed in immunocompetent patients with chronic HCV infection. High viral load and viral genotype 1b are widely accepted as predictors of unresponsiveness to antiviral therapy in immunocompetent patients with chronic HCV infection [7,8]. In contrast, we found that pretreatment viral titre had no influence on the efficacy of the combination therapy in transplant recipients under immunosuppressive conditions, and a considerable number of patients with a high viral load of genotype 1b HCV underwent an early decline in HCV RNA and achieved SVR after the administration of IFN- α 2b plus RBV. These findings suggest the presence of other host or viral factors that might influence responsiveness to IFN- α 2b plus RBV combination therapy in highly viraemic patients under immunosuppressive conditions.

Interestingly, when assessing viral factors that might influence responsiveness to antiviral treatment, we found that novel defective HCV clones that contain large deletions in the viral genome are present in the serum of recurrent hepatitis C patients with high viral load after LDLT. These defective clones occur widely in both RNA and DNA viruses

in bacteria, plants and animals [25–31]. In particular, RNA viruses have the ability to change rapidly and frequently generate not only new strains but also defective interfering RNAs [32].

Although the precise reason for the development of such defective HCV RNA in patients with recurrent hepatitis C after LDLT is unclear at present, an impaired host immune response as a result of immunosuppressive treatment might somehow be involved in the appearance of these defective strains in transplant recipients. Similar findings have been reported in HBV-related transplant recipients, in which precore defective HBV clones occur in the sera during fulminant reinfection after liver transplantation [33]. Further analyses are required to clarify the relationship between the host immunity and the presence of defective HCV clones.

Few reports have identified defective HCV in patients with HCV infection. Yeh *et al.* [34] detected defective HCV with a truncated core protein in the ascites of a patient with HCC in association with intact HCV in the sera of the same patient. Another study has reported that sequences of the HCV core region in the liver tissues of HCC patients have some nucleotide deletions and mutations that result in a truncated core protein [35]. In contrast to these reports, all defective HCV clones detected in transplant recipients examined in this study had deletions in the large region spanning E1 and E2. It is unclear whether these defective viral clones are capable of replicating in hepatocytes. In tombusvirus, incomplete clones cannot replicate by themselves; however, their replication is rescued by the concurrent presence of homologous helper viruses [25]. In this regard, all of our patients with defective HCV RNA clones also had full-length HCV RNA in their sera. Accordingly, it is possible that coexisting full-length HCV serves as a helper sequence, enabling the encapsulation and secretion of the defective viral genome.

An important finding of this study is that six of the eight patients who lacked evidence of circulating defective virus showed a prompt decline in serum HCV RNA in response to antiviral therapy, whereas all patients with the defective strains responded poorly to IFN- α 2b plus RBV combination therapy. When we investigated the relationship between the presence of defective HCV and the virological response to IFN therapy in immunocompetent patients with chronic hepatitis C, non-SVR cases were more likely to have defective clones than SVR cases; however, the influence of the defective clones did not reach statistical significance (unpublished data). Thus, further analyses are required to assess the possible role of defective HCV clones in immunocompetent patients with chronic hepatitis C. The reason for this remarkable difference in response to antiviral therapy between patients with and without defective clones remains to be determined; however, it may be reasonable to speculate that the defective strains modulate the course of the disease by affecting the activity of wild-type viruses, as many defective interfering viral RNA can compete with the helper

virus during replication or during other steps in the infectious cycle.

In conclusion, IFN- α 2b plus RBV can achieve SVR in one third of patients with recurrent hepatitis C after LDLT, despite infection with genotype 1b and a very high viral load. This work provides the first evidence that defective HCV RNA is present in the sera of some of highly viraemic patients under immunosuppressive conditions after liver transplantation, which may affect viral response to IFN- α 2b plus RBV combination therapy. Further studies are required to assess the clinical significance of these defective HCV clones.

ACKNOWLEDGEMENTS

The authors thank Drs Kunitada Shimotohno, Makoto Hijikata and Koichi Watashi for their useful advice and kindly providing pM1LE plasmid. The authors thank Dr Hironori Haga for the pathological comments. This study was supported by a grant-in-aid for Scientific Research (15209024 and 16790378) from the Japan Society for the Promotion of Science (JSPS).

REFERENCES

- 1 Konig V, Bauditz J, Lobeck H *et al.* Hepatitis C virus reinfection in allografts after orthotopic liver transplantation. *Hepatology* 1992; 16: 1137–1143.
- 2 Feray C, Gigou M, Samuel D *et al.* The course of hepatitis C virus infection after liver transplantation. *Hepatology* 1994; 20: 1137–1143.
- 3 Gane EJ, Portmann BC, Naoumov NV *et al.* Long-term outcome of hepatitis C infection after liver transplantation. *N Engl J Med* 1996; 334: 815–820.
- 4 Garcia-Retortillo M, Forns X, Llovet JM *et al.* Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. *Hepatology* 2004; 40: 699–707.
- 5 Gaglio PJ, Malireddy S, Levitt BS *et al.* Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. *Liver Transpl* 2003; 9: 1028–1035.
- 6 Samuel D, Bizollon T, Feray C *et al.* Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. *Gastroenterology* 2003; 124: 642–650.
- 7 Weiland O. Treatment of naive patients with chronic hepatitis C. *J Hepatol* 1999; 31(Suppl. 1): 168–173.
- 8 Iino S, Tomita E, Kumada H *et al.* Prediction of treatment outcome with daily high-dose IFN alpha-2b plus ribavirin in patients with chronic hepatitis C with genotype 1b and high HCV RNA levels: relationship of baseline viral levels and viral dynamics during and after therapy. *Hepatol Res* 2004; 30: 63–70.
- 9 Firpi RJ, Abdelmalek MF, Soldevila-Pico C *et al.* Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. *Liver Transpl* 2002; 8: 1000–1006.

- 10 Lavezzo B, Franchello A, Smedile A *et al.* Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. *J Hepatol* 2002; 37: 247–252.
- 11 Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. *Lancet* 1997; 349: 825–832.
- 12 Inomata Y, Tanaka K, Egawa H *et al.* The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. *Transplantation* 1996; 61: 247–252.
- 13 Iwai A, Marusawa H, Matsuzawa S *et al.* Siah-1L: a novel transcript variant belonging to the human Siah family of proteins, regulates beta-catenin activity in a p53-dependent manner. *Oncogene* 2004; 23: 7593–7600.
- 14 Marusawa H, Uemoto S, Hijikata M *et al.* Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. *Hepatology* 2000; 31: 488–495.
- 15 Kishine H, Sugiyama K, Hijikata M *et al.* Subgenomic replicon derived from a cell line infected with the hepatitis C virus. *Biochem Biophys Res Commun* 2002; 293: 993–999.
- 16 Young KC, Chang TT, Hsiao WC, Cheng PN, Chen SH, Jen CM. A reverse-transcription competitive PCR assay based on chemiluminescence hybridization for detection and quantification of hepatitis C virus RNA. *J Virol Methods* 2002; 103: 27–39.
- 17 Han JH, Shyamala V, Richman KH *et al.* Characterization of the terminal regions of hepatitis C viral RNA: identification of conserved sequences in the 5' untranslated region and poly(A) tails at the 3' end. *Proc Natl Acad Sci USA* 1991; 88: 1711–1715.
- 18 Kato N, Hijikata M, Ootsuyama Y *et al.* Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. *Proc Natl Acad Sci USA* 1990; 87: 9524–9528.
- 19 Okamoto H, Okada S, Sugiyama Y *et al.* The 5'-terminal sequence of the hepatitis C virus genome. *Jpn J Exp Med* 1990; 60: 167–177.
- 20 Kunkel TA, Bebenek K. DNA replication fidelity. *Annu Rev Biochem* 2000; 69: 497–529.
- 21 Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil AO. Recurrent hepatitis C after liver transplantation: a non-randomized trial of interferon alfa alone versus interferon alfa and ribavirin. *Liver Transpl* 2001; 7: 863–869.
- 22 Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. *J Hepatol* 2004; 40: 669–674.
- 23 Bekkering FC, Stalgis C, McHutchison JG, Brouwer JT, Perelson AS. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. *Hepatology* 2001; 33: 419–423.
- 24 Castro FJ, Esteban JI, Juarez A *et al.* Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C. *J Viral Hepat* 2002; 9: 202–207.
- 25 Cheng CP, Pogany J, Nagy PD. Mechanism of DI RNA formation in tombusviruses: dissecting the requirement for primer extension by the tombusvirus RNA dependent RNA polymerase in vitro. *Virology* 2002; 304: 460–473.
- 26 Fitchen JH, Beachy RN. Genetically engineered protection against viruses in transgenic plants. *Annu Rev Microbiol* 1993; 47: 739–763.
- 27 Morozov VA, Lagaye S, Taylor GP, Matutes E, Weiss RA. Chimeric matrix proteins encoded by defective proviruses with large internal deletions in human T-cell leukemia virus type 1-infected humans. *J Virol* 2000; 74: 3933–3940.
- 28 Becher P, Orlich M, Konig M, Thiel HJ. Nonhomologous RNA recombination in bovine viral diarrhea virus: molecular characterization of a variety of subgenomic RNAs isolated during an outbreak of fatal mucosal disease. *J Virol* 1999; 73: 5646–5653.
- 29 Molenkamp R, Greve S, Spaan WJ, Snijder EJ. Efficient homologous RNA recombination and requirement for an open reading frame during replication of equine arteritis virus defective interfering RNAs. *J Virol* 2000; 74: 9062–9070.
- 30 Sommer G, Gunther S, Sterneck M, Otto S, Will H. A new class of defective hepatitis B virus genomes with an internal poly(dA) sequence. *Virology* 1997; 239: 402–412.
- 31 Renjifo B, Chou K, Soto Ramirez L, Garcia Vallejo F, Essex M. Human T cell leukemia virus type I (HTLV-I) molecular genotypes and disease outcome. *J Acquir Immune Defic Syndr Hum Retrovirol* 1996; 13(Suppl. 1): S146–S153.
- 32 Strauss JH, Strauss EG. Evolution of RNA viruses. *Annu Rev Microbiol* 1988; 42: 657–683.
- 33 Sterneck M, Gunther S, Gerlach J *et al.* Hepatitis B virus sequence changes evolving in liver transplant recipients with fulminant hepatitis. *J Hepatol* 1997; 26: 754–764.
- 34 Yeh CT, Lu SC, Chu CM, Liaw YF. Molecular cloning of a defective hepatitis C virus genome from the ascitic fluid of a patient with hepatocellular carcinoma. *J Gen Virol* 1997; 78: 2761–2770.
- 35 Ruster B, Zeuzem S, Roth WK. Hepatitis C virus sequences encoding truncated core proteins detected in a hepatocellular carcinoma. *Biochem Biophys Res Commun* 1996; 219: 911–915.

Classification of Human Liver Transplant Recipients by their Preoperative CD8⁺ T Cell Subpopulation and its Relation to Outcome

Koichi Tanaka,¹ Kazue Ozawa,² Satoshi Teramukai,³ Yasutsugu Takada,¹ Hiroto Egawa,¹ Satoshi Kaihara,¹ Yasuhiro Fujimoto,¹ Yasuhiro Ogura,¹ Mureo Kasahara,¹ Masako Ono,² Hiroshi Sato,⁴ Kenji Takai,⁵ Masanori Fukushima,³ and Nagahiro Minato⁶

¹Department of Transplantation and Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Hepatic Disease Research Institute, Shiga, Japan, ³Division of Clinical Trial Design and Management, Translational Research Center, Kyoto University Hospital, Kyoto, Japan, ⁴Division of Bioscience, Shiga University of Medical Science, Shiga, Japan, ⁵SRL Inc., Tokyo, Japan, and ⁶Department of Immunology and Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

The primed status of T cells is markedly different among liver transplant recipients, due to a lifetime of antigen exposure and reduced thymopoiesis by aging, and diseases. This study aims to characterize the preoperative immunological status of CD8⁺ T cell subpopulations and relate it to the outcome for liver transplant recipients. We classified 112 liver transplant recipients into 5 groups, based on hierarchical clustering of the CD8⁺CD45 isoform proportion of T cells. In Groups I and II (pediatric), the naive T cell proportion was more than 50%. In adult recipients, Group III was characterized by a naive T cell proportion of 50%, Group IV had the greatest effector/memory T cells (EM), and Group V had the greatest proportion of effector T cells. In Groups IV and V, the effector T cell proportion was considerably higher, and was accompanied by marked downregulation of the CD27⁺CD28⁺ subsets and upregulation of interferon gamma (IFN)- γ , tumor necrosis factor-alpha, and perforin expression. Group V recipients tended to be complicated postoperatively, with a significantly reduced survival rate (1 yr, 66.8%) and markedly reduced Eastern Cooperative Oncology Group performance status. *Liver Transpl* 12:792-800, 2006.

© 2006 AASLD.

Received August 22 2005; accepted December 1, 2005.

Following liver transplantation, various factors have been found to contribute to graft dysfunction, including etiology of liver disease, recipient and donor age,¹ and retransplantation, tissue damage during organ retrieval, storage and surgery, and insufficient hepatic mass.² Immunity after organ transplantation involves a continuing battle, with chronic stimulation by various persisting antigens such as alloantigen and infections. After liver transplantation, large numbers of donor dendritic cells migrate to the recipients' secondary lymphoid tissues, notably the spleen and lymphoid organs—sites where naive T cells

react with alloantigen-loaded dendritic cells and differentiate into effector and memory T cells. However, the postoperative alloreactive response is greatly affected by the immunological status of recipients prior to transplantation, itself related to age and disease status. Aging increases the proportion of memory phenotype T cells, probably reflecting cumulative exposure to environmental antigens and to a reduced thymic T cell supply.³ The proportion of memory phenotype T cells may be affected by morbidities such as chronic viral infection and other bacterial and fungus infections. After transplantation,

Abbreviations: LDLT, living donor liver transplantation; HBV, hepatitis B virus; HCV, hepatitis C virus; FITC, fluorescein isothiocyanate; PE, phycoerythrin; CCR7, chemokine receptor 7; IFN- γ , interferon-gamma; naive T cell subsets, CD45RO⁻CCR7⁺; CM, central/memory T cell subsets, CD45RO⁺CCR7⁺; EM, effector/memory T cell subsets, CD45RO⁺CCR7⁻; effector T cell subsets, CD45RO⁻CCR7⁻; CTL, cytotoxic T lymphocyte; HLA, human leukocyte antigen.

Supported in part by the Scientific Research Fund of the Ministry of Education, Science and Culture, Japan (13204041, 13307038, and 15390394).

Address reprint requests to Kazue Ozawa, Hepatic Disease Research Institute, 13-45 Uchidehama, Otsu, Shiga 520-0806, Japan. Telephone: 81-77-521-6404; FAX: 81-77-521-6404; E-mail: kanzou@vesta.ocn.ne.jp

DOI 10.1002/lt.20705

Published online in Wiley InterScience (www.interscience.wiley.com).

immunosuppression can modify infectious pathogenic pathways. In particular, postoperative infection is still the most common cause of death in liver transplant recipients. In host defense, infected cells are eliminated by cytotoxic CD8⁺ T cells, with help from the CD4 helper T cells.^{4,5} The chemokine receptor CCR7 controls homing of CD8⁺ T cells to secondary lymphoid organs, and divides human memory T cells into 3 functionally distinct subsets: central/memory (CM), effector/memory (EM), and effector T cells.⁶ Also, expression of the costimulatory receptors CD28 and CD27 is associated with different stages of CD8⁺ T cell differentiation in persistent virus infection in humans.⁷ We therefore set out to identify the immune risk phenotype corresponding to mortality according to the degree of CD8⁺ T cell cytotoxic activity along which sequential downregulation of the CCR7 and CD27⁺CD28⁺ subsets occurs, accompanied by upregulation of cytotoxic factors.

Living donor liver transplantation (LDLT) is an established therapeutic modality for children and adults with end-stage liver disease. At Kyoto University we began a pediatric LDLT program in 1990⁸⁻¹⁰ and an adult program in 1998.¹¹⁻¹³ By August 2004 we had performed more than 1,000 LDLTs. The indications for LDLT have been expanded to include terminal liver disease associated with hepatitis C or B virus (HCV or HBV) infection in adults. HCV-associated end-stage liver disease has recently become one of the most common indications in adult LDLT series.¹⁴ Although HBV has been overcome by antiviral treatments, HCV infection in immunosuppressed transplant recipients usually leads to faster and more severe HCV recurrence, in contrast to immunocompetent individuals;^{15,16} it progresses to significant fibrosis and approximately 30% cirrhosis at 5 yr after liver transplantation.¹⁷

The present study aims to identify any characteristics of the pretransplantation CD8⁺ subpopulation—the immune risk phenotype—that correlate with postoperative complications in heterogeneous recipients.

PATIENTS AND METHODS

Patients and Graft

The study involved 112 subjects who had undergone standard LDLT between 2002 and 2005 at Kyoto University Hospital. Their ages ranged from 1 month to 67 yr. The patients were followed up from the time of transplantation until July 2005 or death. The median follow-up period was 1.9 yr after LDLT (range: 7 months to 2.8 yr). No patients received antiviral therapy after LDLT. HCV- and HBV-positive donors were not used. Written informed consent was obtained before the start of the study, which was approved by the Ethics Committee of Kyoto University Hospital and was conducted in accordance with the Declaration of Helsinki of 1975 as revised in 1996.

Immunosuppression

All patients underwent standard LDLT.¹⁸ The initial immunosuppression regime after LDLT was tacrolimus or cyclosporin with corticosteroids. Administration of tacrolimus (1.5 mg by mouth every 12 hours) was begun on the evening of the day after the operation, according to our standard procedure.¹⁹ Doses were adjusted according to the whole-blood trough concentration, which was measured daily about 12 hours after the evening dose. The target whole-blood trough level was between 10 and 15 ng/mL during the first 3 weeks and approximately 10 ng/mL at the end of the first month; in the outpatient stage it was maintained between 5 and 10 ng/mL. The initial dose of steroids was reduced rapidly, and was withdrawn totally by 3-6 months after transplantation. Methylprednisolone (1 mg/kg) was given intravenously every 12 hours for 3 days, starting on the day of surgery, after which prednisone (0.5 mg/kg) was given for 3 days. On day 7 the prednisone was reduced to a daily maintenance level of 0.3 mg/kg, given orally.

Definition and Treatment of Acute Graft Rejection

In cases of clinical or laboratory signs of acute graft rejection, a liver biopsy was performed percutaneously. The specimens were graded according to the Banff criteria²⁰ as mild, moderate, or severe graft rejection. After diagnosis of acute graft rejection was confirmed, patients received a 3- to 5-day course of intravenous steroid bolus therapy (10 mg/kg). Graft loss was defined by death or retransplantation.

Definition of Infectious Complication

A bacterial, viral, or fungal infection was assumed if clinical or laboratory signs of acute infection or positive serologic markers or culture were found. In proven cases of infection, the treatment followed general recommendations.

Virology Assay

Serum qualitative HCV-ribonucleic acid was determined by the polymerase chain reaction method using a commercially available assay (Amplicor HCV; Roche Molecular Systems, Pleasanton, CA). The HCV genotype was determined with a system based on polymerase chain reaction using genotype-specific primers.²¹ In the 26 recipients assayed, 25 had pretransplantation HCV 1b genotype.

Tissue Typing

Serologic tissue typing was performed in all patients for human leukocyte antigen (HLA)-A, HLA-B (Bw), HLA-C, HLA-DR, and HLA-DQ loci.

Flow Cytometry

In recent years, major histocompatibility complex class I tetramer technology has been applied to clarify the